Bristol Myers Squibb Reaches $239M Settlement Over Multiple Sclerosis and Psoriasis Drugs

Bristol Myers Squibb (BMY.N), reached a $239 million settlement of claims that former Celgene shareholders were defrauded about prospects for the psoriasis drug Otezla, and multiple sclerosis treatment now known as Zeposia.

A preliminary settlement of the 7-1/2-year-old class action was filed on Tuesday night in the federal court in Newark, New Jersey, and requires a judge’s approval.

Read more at Reuters